In the second of a four-part series guest-hosting the Gastroenterology Learning Network’s IBD Drive Time, Dr. Rubin discusses the impact of the obstacles of the prior authorization process on patients and providers. Listen here, as he is joined by David Choi, specialty clinical pharmacist and associate director of the IBD center at UChicago, and Mona Shah, senior director of policy and strategy at Community Catalyst, a nonprofit organization that aims to ground healthcare policy and practice change goals within community.

Take a listen to Dr. Rubin discuss the impact of inflammatory bowel disease on sexual function with University of Chicago’s GI psychologist, Dr. Alyse Bedell, and pelvic floor physical therapist, Sarah Macaraeg.

Click here to listen to Dr. Rubin discuss the importance of head-to-head and comparative trials, combination therapies, optimization with timing, escalation and de-escalation, and how we should approach new therapies.

Intestinal ultrasound (IUS) is a disease monitoring modality for IBD that is new to the United States. Dr. Noa Krugliak Cleveland is one of just a handful of experts in the country on IUS. Click here to listen to the full conversation where she provides an overview of her experience with ultrasound: from patients’ responses to insurance processes to integrating it across North America, and everything in between.

Click here to read Conference Coverage on Dr. Rubin’s talk at AIBD Virtual Regionals 2023, “JAK Inhibitors: Efficacy and Safety.” He details the pivotal clinical trials that help us understand JAK-inhibitors, as well as real-world evidence of their success in patients.

Click here to watch the full video of Dr. Rubin’s presentation on exit strategies from maintenance therapy, including discussion of the reasons for why, when, how, and if you should stop IBD therapy with specific focus on biologics, 5-ASA, and azathioprine.

Dr. Rubin hosted four episodes of MedEd Talks Gastroenterology’s Pearls from the Pros on IBD Management, featuring several colleagues to discuss best practices in using different classes of IBD therapies. Dr. Rubin spoke with Dr. Bruce Sands, Gastroenterologist and Professor of Medicine at Mount Sinai, about best practices in anti-IL-12/23 therapies. With Dr. Millie Long, Associate Professor in the Department of Medicine, Division of Gastroenterology and Hepatology at University of North Carolina at Chapel Hill, Dr. Rubin discussed JAK inhibitors and their role in clinical practice. Dr. Stephen Hanauer, Professor of Medicine in Gastroenterology and Hepatology at Northwestern University, shared his expertise on Anti-TNF therapy. Finally, Dr. Rubin talked about small-molecule therapies, including S1P receptor modulation and anti-integrin therapies, with Dr. Maria T. Abreu, Professor of Medicine and Director of the Crohn’s and Colitis Center at the University of Miami.

Watch David T. Rubin accept the 2020 Sherman Prize, which is awarded to IBD clinicians, surgeons, researchers and/or academics with extraordinary track records of achievement, making exceptional and pioneering contributions that transform IBD care.

Originally presented at the Crohn’s and Colitis Congress with colleagues Fabio Cominelli, MD, PhD, of Case Western Reserve University, and Siddharth Singh, MD, of the University of California San Diego, Rubin highlighted the importance of choosing the most appropriate journal, sending pre-submission inquiries, creating a compelling cover letter and more.

To watch the complete video, click here